New Allied Health Membership

SNO represents over 2,800 professionals dedicated to promoting advances in neuro-oncology through research and education. As part of this commitment, SNO is pleased to introduce a new category of membership for Allied Health Professionals. This category of memberships is designed for non-physician clinical health care professionals, including, advance practice professionals, nurses, physician assistants, pharmacists, and others who spend most of their professional activity on the treatment and care of patients with brain and CNS tumors. For full details and to apply click here.

SNO Public Policy - Progress on Capitol Hill

The Fiscal Year 2022 Omnibus package from Congress brought significant wins for the Society for Neuro-Oncology. The package includes:

- $130 million for the Department of Defense Peer-Reviewed Cancer Research Program, an increase of $15 million, while “brain cancer” and “pediatric brain tumors” remained eligible funding categories.
- The National Institutes of Health saw an increase of 5% in funding, totaling $45 billion.
- The National Cancer Institute received nearly $7 billion in funding, an increase of nearly $354 million.
- President Biden’s new agency, the Advanced Research Projects Agency for Health, received $1 billion in funding.

These wins show that the Society for Neuro-Oncology’s Public Policy Committee has successfully pushed Congress and the Biden Administration to realize that brain tumors are not a partisan issue and deserves more research funding to provide much-needed breakthroughs. If you have any questions or need additional information, please don’t hesitate to contact us snodigest@soc-neuro-onc.org.

Educational Programming

Cell-free DNA from CSF in pediatric, adolescent
and young adult patients

Dr. Iyad Alnahhas interviews Dr. Matthias Karajannis about his and his team's recent manuscript entitled: "Next-generation sequencing of cerebrospinal fluid for clinical molecular diagnostics in pediatric, adolescent and young adult (AYA) brain tumor patients", published in Neuro-Oncology in February 2022. Listen to the podcast.

From The Journals

From Neuro-Oncology Advances

Prognostic value of MGMT methylation in IDH mutant gliomas

Patients with isocitrate dehydrogenase (IDH) mutant gliomas have been associated with longer survival time than those that are IDH wild-type. Previous studies have shown the prognostic value of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation for glioblastoma multiforme (GBM), which are predominantly IDH wild-type. Little is known of the prognostic value of MGMT methylation status for IDH mutant gliomas. Click here to read the full article.

Upcoming Webinar

The Society for Neuro-Oncology's Molecular Pathology Special Interest Track is pleased to announce the quarterly event for the SNO Pathology FAST (First Author Series Talk) webinar series. The webinar entitled Spatial Immunogenomic Heterogeneity of Malignant Brain Tumors will occur live on Monday May 16, 2022, at 1:00pm - 2:00pm EDT. Click here to register.

Featured Clinical Case

39 year-old man with multiply recurrent BRAF(V600E)-mutant pleomorphic xanthoastrocytoma

Submitted by Karisa Schreck, MD PhD, ksort1@jhmi.edu Department of Neurology, Johns
We welcome interesting and challenging case submissions with teaching points by all members. This may focus on clinical management, pathology and diagnostic quandary, imaging highlight, operative nuance, or other salient points that may be of interest to the membership of SNO. Case submissions are limited to 250 words with 1-2 figures. Please send your submissions to: snodigest@soc-neuro-onc.org

SNO Career Center

This Week's Featured Listing
University of Arizona Cancer Center is actively recruiting an experienced, board-certified Neuro-Oncologist. The hired physician will have the opportunity to practice in a cutting-edge, clinical multidisciplinary environment alongside active research programs. Click here to apply or see other postings!

Upcoming SNO and SNO Affiliated Events

2022 SNO Annual Meeting and Education Day - Call for Abstracts
Abstract deadline - June 1, 2022
This deadline will not be extended.
For information on the submission categories and requirements, please click here.
To submit an abstract, please click here.

The 20th International Symposium of Pediatric Neuro-Oncology (ISPNO 2022)
June 12-15, 2022, in Hamburg
Register Here
For information about travel grants for LMIC countries, please click here.

2nd Annual Conference on Clinical Trials and Brain Metastases
August 12-13, 2022
Registration and Accommodations Coming Soon.

Sponsorship Opportunities

If you are interested in exhibiting or sponsoring at one of our upcoming events, please contact partnerships@soc-neuro-onc.org for your customized package today. To view the prospectus for the 2nd Annual Conference on Clinical Trials and Brain Metastases, click here. To view the prospectus for the 2022 SNO Annual Meeting and Education Day, click here. If you are interested in hosting an investigator meeting or social event concurrently during our annual meeting, please contact gabrielle@soc-neuro-onc.org.